Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Trade Desk Inc (TTD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Trade Desk Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Trade Desk Inc trades at $19.71 (market cap $9.18B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.3× Trade Desk Inc's market cap. Which is the better fit depends on your goals.
| ALNY | TTD | |
|---|---|---|
Market Cap | $39.89B | $9.18B |
Sector | Health | Technology |
52-Week High | $491.22 | $89.76 |
52-Week Low | $278.09 | $17.33 |
Enterprise Value | $38.15B | $8.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
The Trade Desk (TTD) trades at $19.53, down 1.11% with bearish technical signals despite strong profitability metrics including 77.83% gross margins and 14.57% net income margin. Recent earnings show mixed results with Q1 2026 missing expectations, while revenue growth has slowed from 2024's peak. The stock faces headwinds from market share competition and a recent 52% decline in H1 2026, though analyst consensus remains positive with a $25.46 price target representing 30% upside potential.
TTD presents a value opportunity with attractive valuation multiples (P/E 22.19, P/S 3.2) and robust cash flow generation, but investors face execution risks amid slowing growth and competitive pressures. The resolution of the Publicis dispute removes a key overhang, though the stock requires sustained earnings beats and market share stabilization to justify analyst optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
